ea0050p058 | Bone and Calcium | SFEBES2017
Al-Hity Shams
, Criseno Sherwin
, Justice Elizabeth
Background: Zoledronic acid infusions are licensed for the treatment of osteoporosis and other bone disorders. Hypocalcaemia, a common side effect, increases the risk of complications. The risk of hypocalcaemia is further increased by a deficiency in 25-OH Vitamin D (VD). Pre-dose screening (PDS) is necessary to detect sub-optimal levels of serum VD and adjusted calcium (AC) early to avoid delayed treatment.Objectives: Audit adhere...